Don't Sit Still And Avoid DVT
"Desk-bound workers at double DVT risk, " reads the headline in The Daily Telegraph. Workers who "sit at a desk for eight hours a day and spend more than three hours without stretching double their risk of developing deep vein thrombosis (DVT)", the newspaper says.
St. Jude Medical Announces U.S. Launch Of TigerWire Steerable Guidewire
St. Jude Medical, Inc. (NYSE:STJ) announced U.S. launch of the TigerWire(TM) Steerable Guidewire. The newest member of the St. Jude Medical GuideRight(TM) family of steerable guidewires, the TigerWire Steerable Guidewire is designed to enhance physicians' ability to steer through challenging peripheral arteries, the vessels that supply blood to the legs and arms.
Studies Point To Benefits Of Personalized Chemotherapy Dose Management In Colorectal Cancer
Can a blood test improve treatment outcomes for colorectal cancer patients? Recently published studies indicate that personalized chemotherapy dose management -- measuring drug levels in patients' blood and adjusting them for optimal dosing -- can substantially reduce severe toxicity and improve efficacy in colorectal cancer.
Heparin Testimonies Before House Committee
Emotions ran high in Washington yesterday, Tuesday 29th April, as a congressional panel listened to tearful and angry testimonies from family members of how their loved ones died after being given contaminated heparin. Manufacturers and industry regulators also told their story, but panel members were very unhappy with their failure to stop the unsafe blood thinner from entering the US from China.
Clumps Of Red And White Blood Cells May Contribute To Sickle Cell Disease
It's long been known that patients with sickle cell disease have malformed, "sickle-shaped" red blood cells which are normally disc-shaped that can cause sudden painful episodes when they block small blood vessels.Now, researchers at the University of North Carolina at Chapel Hill School of Medicine have shown that blood from sickle cell patients also contains clumps, or aggregates, of red and white blood cells that may contribute to the blockages.
Viscosity Enhancers That Thicken Blood Are Highly Effective In Treating Severe Hemorrhage
Intravenous administration of isotonic fluids is the standard emergency treatment in the U.S. for patients with severe blood loss, but UC San Diego bioengineering researchers have reported improved resuscitation with a radically different approach. Building on earlier studies in humans that have shown benefits of intravenous fluids that are eight times saltier than normal saline, the researchers combined hypertonic saline with viscosity enhancers that thicken blood.
Publication Offers Labs Consensus Recommendations For Diagnosing Parasitic Diseases
ASM Press announces the latest addition to its Cumulative Techniques and Procedures in Clinical Microbiology (Cumitechs) publication series: Cumitech 46 -- Laboratory Procedures for Diagnosis of Blood-Borne Parasitic Diseases."This Cumitech is intended to provide guidance to the laboratory personnel and other members of the patient care team in the appropriate selection, ordering and application of tests for the diagnosis and management of blood-borne parasitic infections.
Tredaptive Recommended For EU Approval For The Treatment Of Mixed Dyslipidaemia And Primary Hypercholesterolaemia
Merck Sharp & Dohme Limited (MSD) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for 'Tredaptive'™ (nicotinic acid/laropiprant, MSD) 1000 mg / 20 mg modified-release tablets for the treatment of mixed dyslipidaemia and primary hypercholesterolaemia.
Lannett Company Receives Approval For Dipyridamole Tablets USP, 25 Mg, 50 Mg, And 75 Mg
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dipyridamole Tablets USP, 25mg, 50mg, and 75mg, the generic equivalent of Persantine Tablets manufactured by Boehringer Ingelheim GmbH.
Ligand Initiates Phase II Trial With LGD-4665 In Idiopathic Thrombocytopenic Purpura
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has initiated a Phase II study of its small-molecule thrombopoietin (TPO) mimetic, LGD-4665. The 24 patient, double-blind placebo-controlled trial is designed to evaluate the safety and efficacy of LGD-4665 in adult patients with idiopathic thrombocytopenic purpura (ITP) over six weeks of treatment.